ASH 2021 | Thoughts on panobinostat’s recent withdrawal from the US market
Paul Richardson, MD, Dana-Farber Cancer Institute, Boston, MA, discusses the recent withdrawal of panobinostat from the US market. The PANORAMA_3 clinical trial evaluating panobinostat in combination with bortezomib and dexamethasone in patients with relapsed/refractory (R/R) multiple myeloma demonstrated an impressive duration of response (DOR) (NCT02654990). The drug was however taken off the market in the US due to regulatory concerns. According to Dr Richardson, panobinostat has still got a role in the R/R setting as it has a distinct mechanism of action and is administered orally, which is advantageous in the context of the COVID-19 pandemic. Although this withdrawal should not affect access to panobinostat outside of the US, Dr Richardson hopes that patients in the US who may benefit from this drug will still be able to receive it. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.
